Biotechnology - Biotechnology, Oncology

Filter

Current filters:

BiotechnologyOncology

Popular Filters

1 to 25 of 607 results

Bristol-Myers enters option deal to acquire F-star Alpha and FS102

28-10-2014

US pharma major Bristol-Myers Squibb has entered into an agreement that provides it with the exclusive…

BiotechnologyBristol-Myers SquibbF-star AlphaFS102Mergers & AcquisitionsOncology

Takeda licenses commercial rights to Mersana Fleximer-ADC

27-10-2014

Just seven months after the collaboration was announced, Japan’s largest drugmaker Takeda Pharmaceutical…

BiotechnologyFleximerLicensingMersana TherapeuticsMillennium PharmaceuticalsOncologyTakeda Pharmaceutical

CTI acquires tosedostat rights from Vernalis and Chroma

CTI acquires tosedostat rights from Vernalis and Chroma

27-10-2014

Blood-related cancer specialist CTI BioPharma has acquired the worldwide rights to tosedostat through…

BiotechnologyChroma TherapeuticsCTI BioPharmaLicensingOncologytosedostatUSAVernalis

WuXi PharmaTech collaborates on genomic profiling for China

24-10-2014

China’s WuXi PharmaTech has entered into a collaboration with USA-based Foundation Medicine to offer…

BiotechnologyChinaFoundation MedicineLicensingOncologyWuXi PharmaTech

Sutro Biopharma and Celgene expand accord; add buyout option

23-10-2014

Sutro Biopharma today announced it has entered into a strategic collaboration and option agreement with…

BiotechnologyCelgene Corp.LicensingMergers & AcquisitionsOncologySutro Biopharma

PhosImmune and PureMHC to collaborate on antibody-based immunotherapies for cancer

PhosImmune and PureMHC to collaborate on antibody-based immunotherapies for cancer

22-10-2014

Clinical-stage oncology biotech company PhosImmune has entered into a license and collaboration agreement…

BiotechnologyLicensingOncologyPhosImmunePureMHCUSA

NewLink Genetics out-licenses NLG919 to Genentech

NewLink Genetics out-licenses NLG919 to Genentech

20-10-2014

US biotech firm NewLink Genetics saw its share price rocket 21.2% in morning trading today, after it…

BiotechnologyGenentechGlobalLicensingNewLink GeneticsNLG919OncologyRoche

Virax to acquire AKTivate and deep AKT inhibitor portfolio

17-10-2014

Australian biotechnology company Virax Holdings will acquire US oncology company AKTivate Therapeutics…

AKTivate TherapeuticsBiotechnologyMergers & AcquisitionsOncologyPathway OncologyVirax Holdings

Aduro expands deal with Janssen to lung cancer; worth up to $817 million

Aduro expands deal with Janssen to lung cancer; worth up to $817 million

17-10-2014

Privately-held US cancer immunotherapy developer Aduro BioTech has entered into its second agreement…

Aduro BioTechBiotechnologyGlobalJanssen BiotechJohnson & JohnsonLicensingOncologyResearch

Russia’s Generium to establish MabThera analogue production

16-10-2014

Generium Group of Companies, one of Russia’s largest producers of innovative drugs, has commissioned…

BiosimilarsBiotechnologyGeneriumMabTheraOncologyProductionRocheRussia

Big Pharma's control over the Russian state drug procurement tenders market slipping away, says Biocad

16-10-2014

Russian pharmaceutical companies are actively squeezing out foreign therapeutic manufacturers from the…

AcellBiaBiocadBiosimilarsBiotechnologyMabTheraMarkets & MarketingOncologyRituxanRocheRussia

Dendreon’s Provenge too expensive to be recommended, says NICE in draft guidance

Dendreon’s Provenge too expensive to be recommended, says NICE in draft guidance

16-10-2014

In preliminary draft guidance issued this morning the UK health costs watchdog the National Institute…

BiotechnologyDendreonOncologyPricingProvengeRegulationUK

Northwest Bio says DCVax-L hospital exemption program under way in Germany

Northwest Bio says DCVax-L hospital exemption program under way in Germany

15-10-2014

US biotech firm Northwest Biotherapeutics, which is developing DCVax personalized immune therapies for…

BiotechnologyDCVax-LGermanyNorthwest BiotherapeuticsOncologyRegulationResearch

NICE preliminary guidance negative on Celgene’s pomalidomide for multiple myeloma

NICE preliminary guidance negative on Celgene’s pomalidomide for multiple myeloma

15-10-2014

UK medical costs watchdog the National Institute for Health and Care Excellence (NICE) has issued preliminary…

BiotechnologyCelgene Corp.ImnovidOncologyPricingRegulationUK

Trials commence on consortium's fully personalized cancer vaccines for glioblastoma

Trials commence on consortium's fully personalized cancer vaccines for glioblastoma

14-10-2014

A consortium funded by the European Union is to advance a new class of fully personalized cancer vaccines…

BioNTechBiotechnologyGermanyimmatics biotechnologiesOncologyResearch

Bristol-Myers Squibb, Pharmacyclics and Janssen team up to test Opdivo and Imbruvica combination

Bristol-Myers Squibb, Pharmacyclics and Janssen team up to test Opdivo and Imbruvica combination

13-10-2014

US drug major Bristol-Myers Squibb, US-based biopharma company Pharmacyclics and Janssen Research and…

BiotechnologyBristol-Myers SquibbEuropeImbruvicaJanssenOncologyOpdivoPharmacyclics

DelMar's lead compound VAL-083 data shows potential to be superior to current treatments in NSCLC

DelMar's lead compound VAL-083 data shows potential to be superior to current treatments in NSCLC

10-10-2014

Clinical stage oncology company DelMar Pharmaceuticals’ lead drug compound VAL-083 has demonstrated…

BiotechnologyDelMar PharmaceuticalsOncologyResearchUSAVAL-083

US orphan designation for DNAtrix’ DNX-2401 in malignant glioma

US orphan designation for DNAtrix’ DNX-2401 in malignant glioma

09-10-2014

US privately-held oncolytic virus expert DNAtrix says that the US Food and Drug Administration has granted…

BiotechnologyDNAtrixDNX-2401OncologyRegulationUSA

Merck Serono links with ICR and Wellcome Trust on anti-cancer drugs

Merck Serono links with ICR and Wellcome Trust on anti-cancer drugs

07-10-2014

German life sciences major Merck KGaA says its biopharma division Merck Serono has entered into a co-development…

BiotechnologyGermanyLicensingMerck KGaAMerck SeronoOncologyResearch

CleveXel Pharma licenses two new oncology patents from SATT Sud Est

CleveXel Pharma licenses two new oncology patents from SATT Sud Est

06-10-2014

French company CleveXel Pharma has been granted a license by the SATT Sud Est, a technology transfer…

BiotechnologyCleveXel PharmaFranceLicensingOncologyPatentsSATT Sud Est

EPIC Biotech conference: essential to prove comercial viability of propositions

EPIC Biotech conference: essential to prove comercial viability of propositions

03-10-2014

The key message from European Partnering and Investment Conference in biotech, held yesterday in London,…

Antibiotics and Infectious diseasesBiotechnologyBoehringer IngelheimCardio-vascularCNS DiseasesFinancialJohnson & JohnsonMerck SeronoOncologyResearch

Prima BioMed to acquire Immutep for $28 million

Prima BioMed to acquire Immutep for $28 million

03-10-2014

France-based Immutep, a late-stage private biopharmaceutical company in the rapidly growing field of…

BiotechnologyFranceImmunologicalsImmutepMergers & AcquisitionsOncologyPrima BioMed

Incyte earns $60 million milestone on European reimbursement for Jakavi

Incyte earns $60 million milestone on European reimbursement for Jakavi

02-10-2014

US biopharma company Incyte says that it has earned a $60 million milestone payment from Swiss pharma…

BiotechnologyEuropeFinancialIncyteJakafiJakaviNovartisOncologyPricing

Oxford BioTherapeutics and Berlin Chemie/Menarini update on $1 billion oncology investment alliance

Oxford BioTherapeutics and Berlin Chemie/Menarini update on $1 billion oncology investment alliance

02-10-2014

UK biotech firm Oxford BioTherapeutics and family-owned Italian Berlin Chemie/Menarini Group have designated…

BiotechnologyItalyMenariniOncologyOxford BioTherapeuticsResearchUK

1 to 25 of 607 results

Parexel

Parexel

Back to top